Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung CancerYi‐Long Wu, Roy S. Herbst, Huu-Vinh Vu et al.|New England Journal of Medicine|2020Cited by 1.7k
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6James Chih‐Hsin Yang, Yi‐Long Wu, Lecia V. Sequist et al.|The Lancet Oncology|2015Cited by 980
Detection and Dynamic Changes of <i>EGFR</i> Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and ChemotherapyTony Mok, Lin Wu, Yi‐Long Wu et al.|Clinical Cancer Research|2015Cited by 469
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA TrialRoy S. Herbst, Masahiro Tsuboi, Yi‐Long Wu et al.|Journal of Clinical Oncology|2023Cited by 386
Vascular Endothelial Growth Factor 189 mRNA Isoform Expression Specifically Correlates With Tumor Angiogenesis, Patient Survival, and Postoperative Relapse in Non–Small-Cell Lung CancerAng Yuan, Yung-Chie Lee, Chong‐Jen Yu et al.|Journal of Clinical Oncology|2001Cited by 208